Down-Regulation of the Oncogene PTTG1 via the KLF6 Tumor Suppressor during Induction of Myeloid Differentiation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chen, Pei Yi ^a,b   Yen, Jui Hung ^a   Kao, Ruey Ho ^b   Chen, Ji Hshiung ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SECURIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KLF6 GENE; LEUKEMIA CELL; MOUSE; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; ONCOGENE PTTG1; PROTEIN BINDING; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTIGENS, CD11B; BINDING SITES; CELL DIFFERENTIATION; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SECURIN; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 84881581952     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071282     Document Type: Article

References (54)

1. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, et al. (1991) t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A 88: 10431-10434.
2. Crans-Vargas HN, Landaw EM, Bhatia S, Sandusky G, Moore TB, et al. (2002) Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood 99: 2617-2619.
3. Shima Y, Kitabayashi I, (2011) Deregulated transcription factors in leukemia. Int J Hematol 94: 134-141.
4. Pei L, Melmed S, (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433-441.
5. Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, et al. (1998) hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17: 2187-2193.
6. Filippella M, Galland F, Kujas M, Young J, Faggiano A, et al. (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65: 536-543.
7. Thompson AD, (2005) Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 579: 3195-3200.
8. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, et al. (2000) Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716-719.
9. Zou H, McGarry TJ, Bernal T, Kirschner MW, (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418-422.
10. Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, et al. (2001) Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 29: 1300-1307.
11. Tong Y, Eigler T, (2009) Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol 43: 179-185.
12. Wang Z, Yu R, Melmed S, (2001) Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 15: 1870-1879.
13. Wang Z, Moro E, Kovacs K, Yu R, Melmed S, (2003) Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A 100: 3428-3432.
14. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, et al. (1999) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156-166.
15. Hamid T, Malik MT, Kakar SS, (2005) Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer 4: 3.
16. Pei L, (2001) Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276: 8484-8491.
17. Ramaswamy S, Ross KN, Lander ES, Golub TR, (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
18. Liao YC, Ruan JW, Lua I, Li MH, Chen WL, et al. (2012) Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene 31: 3086-3097.
19. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, et al. (2003) Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 88: 2341-2347.
20. Vlotides G, Eigler T, Melmed S, (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28: 165-186.
21. Saez C, Pereda T, Borrero JJ, Espina A, Romero F, et al. (2002) Expression of hpttg proto-oncogene in lymphoid neoplasias. Oncogene 21: 8173-8177.
22. Espina AG, Mendez-Vidal C, Moreno-Mateos MA, Saez C, Romero-Franco A, et al. (2009) Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol Biol Cell 20: 3353-3362.
23. Ishitsuka Y, Kawachi Y, Taguchi S, Maruyama H, Fujisawa Y, et al. (2012) Pituitary tumor-transforming gene 1 enhances proliferation and suppresses early differentiation of keratinocytes. J Invest Dermatol 132: 1775-1784.
24. Rubinek T, Chesnokova V, Wolf I, Wawrowsky K, Vlotides G, et al. (2007) Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. Am J Physiol Cell Physiol 293: C1082-1092.
25. White SL, Belov L, Barber N, Hodgkin PD, Christopherson RI, (2005) Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha,25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res 29: 1141-1151.
26. Kohro T, Tanaka T, Murakami T, Wada Y, Aburatani H, et al. (2004) A comparison of differences in the gene expression profiles of phorbol 12-myristate 13-acetate differentiated THP-1 cells and human monocyte-derived macrophage. J Atheroscler Thromb 11: 88-97.
27. Lee UE, Ghiassi-Nejad Z, Paris AJ, Yea S, Narla G, et al. (2010) Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett 584: 1006-1010.
28. Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, et al. (2004) A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene 23: 8196-8205.
29. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, et al. (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257: 7847-7851.
30. Das D, Pintucci G, Stern A, (2000) MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett 472: 50-52.
31. Matsumoto E, Hatanaka M, Bohgaki M, Maeda S, (2006) PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells. Kobe J Med Sci 52: 181-194.
32. Shivdasani RA, Orkin SH, (1996) The transcriptional control of hematopoiesis. Blood 87: 4025-4039.
33. Clem AL, Hamid T, Kakar SS, (2003) Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 322: 113-121.
34. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X, (2003) DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 278: 462-470.
35. Zhou C, Liu S, Zhou X, Xue L, Quan L, et al. (2005) Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer 113: 891-898.
36. Hlubek F, Pfeiffer S, Budczies J, Spaderna S, Jung A, et al. (2006) Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer 94: 1672-1677.
37. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S, (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5: 1317-1321.
38. Heaney AP, Fernando M, Melmed S, (2002) Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109: 277-283.
39. Tfelt-Hansen J, Yano S, Bandyopadhyay S, Carroll R, Brown EM, et al. (2004) Expression of pituitary tumor transforming gene (PTTG) and its binding protein in human astrocytes and astrocytoma cells: function and regulation of PTTG in U87 astrocytoma cells. Endocrinology 145: 4222-4231.
40. Li D, Yea S, Li S, Chen Z, Narla G, et al. (2005) Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem 280: 26941-26952.
41. DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, et al. (2006) E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 25: 6026-6031.
42. Narla G, Heath KE, Reeves HL, Li D, Giono LE, et al. (2001) KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294: 2563-2566.
43. Cao Z, Sun X, Icli B, Wara AK, Feinberg MW, (2010) Role of Kruppel-like factors in leukocyte development, function, and disease. Blood 116: 4404-4414.
44. Matsumoto N, Kubo A, Liu H, Akita K, Laub F, et al. (2006) Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357-1365.
45. Humbert M, Halter V, Shan D, Laedrach J, Leibundgut EO, et al. (2011) Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leuk Res 35: 909-913.
46. Miranda MB, McGuire TF, Johnson DE, (2002) Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 16: 683-692.
47. Tahara E, Kadara H, Lacroix L, Lotan D, Lotan R, (2009) Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 8: 801-807.
48. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, et al. (2006) Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol Endocrinol 20: 3321-3335.
49. Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, et al. (2000) Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19: 403-409.
50. Tong Y, Tan Y, Zhou C, Melmed S, (2007) Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26: 5596-5605.
51. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564-10572.
52. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, et al. (2007) In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26: 4428-4434.
53. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, et al. (2004) Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 64: 3885-3891.
54. Rovera G, Olashaw N, Meo P, (1980) Terminal differentiation in human promyelocytic leukaemic cells in the absence of DNA synthesis. Nature 284: 69-70.